Reparixin
- Generic Name
- Reparixin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C14H21NO3S
- CAS Number
- 266359-83-5
- Unique Ingredient Identifier
- U604E1NB3K
- Background
Reparixin has been used in trials studying the treatment and prevention of Breast Cancer, Metastatic Breast Cancer, Pancreatectomy for Chronic Pancreatitis, Islet Transplantation in Diabetes Mellitus Type 1, and Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus.
- Associated Conditions
- -
- Associated Therapies
- -
Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation
- Conditions
- Ischemia-reperfusion Injury in Liver TransplantEarly Allograft Dysfunction
- Interventions
- Other: ControlDrug: Reparixin
- First Posted Date
- 2017-01-25
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Dompé Farmaceutici S.p.A
- Target Recruit Count
- 40
- Registration Number
- NCT03031470
- Locations
- 🇧🇾
Healthcare Organization "9th City Clinical Hospital", Minsk, Belarus
🇷🇺State Budgetary Educational Institution of Higher Professional Education "First Saint Petersburg State Medical University n.a. I.P. Pavlov" of the Ministry of Health of the Russian Federation, St. Petersburg, Saint Petersburg, Russian Federation
🇷🇺State Budgetary Health Institution of Novosibirsk Region "State Novosibirsk Regional Clinical Hospital", Novosibirsk, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.